98%
921
2 minutes
20
Cap color is a critical commercial trait in mushrooms, yet the molecular mechanisms underlying its temperature-induced variation remain poorly understood. This study integrated metabolomic and transcriptomic approaches to identify key metabolites and genes associated with the transition of cap color from white to wine-red under different temperature conditions. Metabolomic analysis identified 1913 metabolites, with flavonoid derivatives such as quercetin-3-O-glucoside and kaempferol-based compounds accumulating preferentially in wine-red mushrooms at high temperatures. Transcriptomic analysis revealed 13,428 differentially expressed genes (DEGs), including 36 structural genes in the flavonoid biosynthesis pathway. Notably, upregulation of (F3'H) and (F3'5'H) was observed in wine-red mushrooms, suggesting their involvement in red pigment production. In contrast, (F3'H) was more highly expressed in yellow mushrooms, indicating isoform-specific hydroxylation activity. Integrated gene-metabolite correlation and network analysis highlighted key enzymes, including phenylalanine ammonia lyase (PAL), flavonoid 3'-hydroxylase (F3'H), and 4-coumarate: coenzyme A ligase (4CL), as central regulators of color-related flavonoid biosynthesis. These findings provide valuable insights into the molecular basis of temperature-induced color variation in and offer potential applications in mushroom breeding and horticulture.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318294 | PMC |
http://dx.doi.org/10.1016/j.fochms.2025.100276 | DOI Listing |
Alzheimers Res Ther
September 2025
Department of Neurology, Saarland University, Kirrberger Straße, 66421, Homburg/Saar, Germany.
Background: Alzheimer's disease (AD) patients and animal models exhibit an altered gut microbiome that is associated with pathological changes in the brain. Intestinal miRNA enters bacteria and regulates bacterial metabolism and proliferation. This study aimed to investigate whether the manipulation of miRNA could alter the gut microbiome and AD pathologies.
View Article and Find Full Text PDFBMC Infect Dis
September 2025
Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
Background: Escherichia coli ST131 and clade H30Rx are the most prevalent extended-spectrum β-lactamase-producing E. coli (ESBL-EC) causing bacteremia and urinary tract infections globally and in Sweden. Previous studies have linked ST131-H30Rx with septic shock and mortality, as well as prolonged carriage.
View Article and Find Full Text PDFSci China Life Sci
September 2025
The State Key Laboratory of Plant Trait Design, CAS Center for Excellence in Molecular Plant Sciences, Shanghai Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, 200032, China.
Nat Aging
September 2025
Aging Biomarker Consortium (ABC), Beijing, China.
The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age-related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual's physiological and molecular state, across diverse Chinese cohorts.
View Article and Find Full Text PDFNat Aging
September 2025
Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway.
Beyond their classical functions as redox cofactors, recent fundamental and clinical research has expanded our understanding of the diverse roles of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) in signaling pathways, epigenetic regulation and energy homeostasis. Moreover, NAD and NADP influence numerous diseases as well as the processes of aging, and are emerging as targets for clinical intervention. Here, we summarize safety, bioavailability and efficacy data from NAD-related clinical trials, focusing on aging and neurodegenerative diseases.
View Article and Find Full Text PDF